Berberine vs. Metformin: The Pilot Trial Behind HbA1c 9.5% to 7.5%
A small 2008 pilot trial put berberine head-to-head with metformin in newly diagnosed type 2 diabetes, and the glucose-lowering effect looked similar. In the berberine group, HbA1c fell from 9.5% to 7.5% in three months. A second trial in 48 people already on treatment saw HbA1c drop from 8.1% to 7.3% and HOMA-IR fall 44.7%. But these were small studies in people with diabetes, and about a third of participants had GI side effects. Here is what the data show, what they don't, and what to know before you think about berberine.
MOTS-c Explained: The 16-Amino-Acid Mitochondrial Peptide That Activated AMPK and Shielded Mice From Diet-Induced Obesity
A tiny 16-amino-acid peptide encoded in mitochondrial DNA, not the nucleus, activated AMPK in muscle and protected mice from diet-induced obesity and insulin resistance in a 2015 Cell Metabolism study. MOTS-c is now one of the most talked-about names in peptide and biohacking circles. But this was a mouse and molecular-discovery paper with no human outcome data, and MOTS-c is not an approved therapy. This article explains what MOTS-c is, how it appears to work through the folate cycle and AMPK, what the mice showed, and what readers should and should not conclude.